Community oncologists play an important role in expanding access to clinical trials. Patel discusses the value of offering ...

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study. Giada Bianchi, MD, discusses tailoring therapy in myeloma, ...

Targeted Therapies in Oncology provides evidence-based news and updates on the most current advances in therapeutics, biomarkers, pathways, biomarkers, molecular profiling, and diagnostic testing with ...

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast ...

Dr. Jason Mouabbi discusses the approach to managing treatment-related hyperglycemia while maintaining cancer treatment for ...

Alicia Morgans, MD, MPH, discusses quality-of-life analyses from the ARANOTE and ARASENS trials and what they show about adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) in ...

Adding stereotactic body radiation therapy (SBRT) or surgery directed at every known metastasis to first-line systemic ...

However, the shift to precision oncology involves therapy based more on molecular profiles and the context of an individual ...

Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated ...

Dr. Jason Mouabbi discusses how available pathway-directed treatment approaches may be differentiated for patients with ...

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively ...

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back ...